Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1756 to 1770 of 7707 results

  1. MRI fusion biopsy systems for diagnosing prostate cancer (DG53)

    Evidence-based recommendations on MRI fusion biopsy systems for diagnosing prostate cancer

  2. Transperineal biopsy for diagnosing prostate cancer (DG54)

    Evidence-based recommendations on transperineal biopsy for diagnosing prostate cancer

  3. Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587

    Awaiting development [GID-TA10519] Expected publication date: TBC

  4. Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]

    Awaiting development [GID-TA10909] Expected publication date: TBC

  5. Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

    Suggested remit - To appraise the clinical and cost effectiveness of fingolimod within its marketing authorisation for treating relapsing multiple sclerosis in ...

  6. Tocilizumab for treating systemic sclerosis (ID1396)

    Awaiting development [GID-TA10346] Expected publication date: TBC

  7. Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

    Awaiting development [GID-TA10453] Expected publication date: TBC

  8. OrganOx metra for liver transplant [ID5116]

    In development [GID-TA11035] Expected publication date: TBC

  9. Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]

    Suggested remit: To appraise the clinical and cost effectiveness of natalizumab within its marketing authorisation for treating highly active relapsing-remittin...

  10. OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

    Awaiting development [GID-HST10022] Expected publication date: TBC

  11. Canakinumab for untreated Schnitzler syndrome [ID4063]

    Suggested remit: To appraise the clinical and cost effectiveness of canakinumab within its marketing authorisation for treating Schnitzler syndrome. ...

  12. STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]

    Awaiting development [GID-TA10279] Expected publication date: TBC

  13. Rivaroxaban for treating chronic heart failure [ID1462]

    Awaiting development [GID-TA10393] Expected publication date: TBC

  14. Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]

    In development [GID-TA10919] Expected publication date: TBC

  15. Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]

    In development [GID-TA10998] Expected publication date: TBC